Nuklearmedizin 2022; 61(02): 159
DOI: 10.1055/s-0042-1746005
Abstracts | NuklearMedizin 2022
WIS-Vortrag
Neurologie

Assessment of 18-F-D2-Deprenyl (18-F-DED) as a Distinctive Biomarker in Multiple System Atrophy and Idiopathic Parkinson’s Disease

Autoren

  • L. Vogler

    1   University Hospital LMU, Department of Nuclear Medicine, Munich

  • S. Katzdobler

    2   University Hospital LMU, Department of Neurology, Munich

  • F. Eckenweber

    1   University Hospital LMU, Department of Nuclear Medicine, Munich

  • C. Palleis

    2   University Hospital LMU, Department of Neurology, Munich

  • S. Lindner

    1   University Hospital LMU, Department of Nuclear Medicine, Munich

  • U. Fietzek

    2   University Hospital LMU, Department of Neurology, Munich

  • B. Nuscher

    3   Ludwig-Maximilians-University, Chair of Metabolic Biochemistry, Biomedical Center (BMC), Munich

  • A. Mueller

    4   Life Molecular Imaging, R&D, Berlin

  • N. Koglin

    4   Life Molecular Imaging, R&D, Berlin

  • A. Stephens

    4   Life Molecular Imaging, R&D, Berlin

  • C. Haass

    3   Ludwig-Maximilians-University, Chair of Metabolic Biochemistry, Biomedical Center (BMC), Munich

  • J. Levin

    2   University Hospital LMU, Department of Neurology, Munich

  • M. Brendel

    1   University Hospital LMU, Department of Nuclear Medicine, Munich
Weitere Informationen
Auch verfügbar auf
 
 

Ziel/Aim Multiple System Atrophy (MSA) is a neurodegenerative disease with a parkinsonian (P) and cerebellar (C) subtype, both of which are accompanied by neuroinflammatory astrogliosis. So far, no biomarker has been established that allows for a diagnostically reliable differentiation between these two and idiopathic Parkinson’s disease (IPS). By targeting increased MAO-B expression in reactive astrocytes with the novel PET tracer [18F]D2-Deprenyl, we hypothesized that significant group differences between MSA and IPS patients can be reliably detected.

Methodik/Methods We acquired 17 dynamic 0–60 min 18-F-DED PET Scans (9 MSA-C, 5 MSA-P, 3 IPS; ~185 MBq) which were analyzed in PMOD together with structural MRI. Distribution volume ratios (DVR) and 30–60 min standardized uptake value ratios (SUVr) with a parietal white matter reference region as well as SUV were obtained in three target regions (putamen, cerebellar white matter, brainstem). PET quantification was intercorrelated and compared between patient groups using a multivariate analysis of variance including age and sex as covariates.

Ergebnisse/Results SUV and SUVr values were highly correlated across target regions (R>0.8; p<0.001), as were SUV and DVR (R>0.6; p<0.001) as well as SUVr and DVR values (R>0.8; p<0.001). Multivariate analyses of SUVr revealed higher putaminal 18-F-DED binding for both MSA-P (+6.5%) and MSA-C (+7.0%) when compared to IPS (p<0.05). 18-F-DED SUVr of the cerebellar white matter was predominantly elevated in MSA-C (+23%) and less in MSA-P (+12%) when compared to IPS at a trend level to significance (p=0.051).

Schlussfolgerungen/Conclusions Our preliminary data indicate that 18-F-DED, as a correlate of elevated MAO-B expression, could potentially be used as a PET imaging biomarker to differentiate between patients with MSA and IPS. Cerebellar white matter MAO-B expression might allow MSA phenotype differentiation, although further analyses with larger sample sizes are needed.


Publikationsverlauf

Artikel online veröffentlicht:
14. April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany